{"id":"best-standard-of-care-bsoc","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL261657","moleculeType":"Small molecule","molecularWeight":"405.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BSoC refers to the established, most effective treatment regimen available for a given condition at the time of trial design. It serves as the control or comparator arm against which investigational drugs are evaluated. The specific mechanism depends entirely on what treatments constitute standard care for the indication being studied.","oneSentence":"Best standard of care (BSoC) is a comparator arm designation used in clinical trials, not a drug with a specific mechanism of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:20.642Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00699751","phase":"PHASE3","title":"A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06-12","conditions":"Hormone Refractory Prostate Cancer, Bone Metastases","enrollment":921},{"nctId":"NCT05670106","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-16","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":62},{"nctId":"NCT03511664","phase":"PHASE3","title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Endocyte","startDate":"2018-05-29","conditions":"Prostate Cancer","enrollment":861}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Best standard of care (BSoC)","genericName":"Best standard of care (BSoC)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}